A multimillion dollar windfall for Icosavax Inc. will help allow the company to launch a COVID-19 vaccination program using its virus-like particle candidate (VLP), IVX-411, that displays the SAR-CoV-2 receptor-binding domain.
DUBLIN – Kiadis Pharma BV has parlayed its €31.9 million (US$37.2 million) stock-based acquisition of Cytosen Therapeutics Inc. last year, which involved an initial outlay of just €14.5 million worth of shares, into a €308 million payday with Sanofi SA.
In Regeneron Pharmaceuticals Inc.’s Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn), the FDA has approved its first ever treatment for the Ebola virus in pediatric and adult patients.
Monday, Oct. 5, was probably the first day of 2020 that SARS-CoV-2 had serious competition for science media attention – by another virus. The Nobel Assembly awarded the 2020 Nobel Prize for Physiology or Medicine to Harvey Alter, Michael Houghton and Charles Rice “for the discovery of hepatitis C virus.”
Anti-infective drugs approved over the last two decades were able to get through the clinical development and FDA approval processes substantially faster than other drugs, according to a new report from the Tufts Center for the Study of Drug Development.
Researchers at the University of Virginia have used a retrospective database analysis to show that the use of nucleoside reverse transcriptase inhibitors for the treatment of HIV or hepatitis B reduced the risk of developing type 2 diabetes by 33%.
PERTH, Australia – Sydney-based Recce Pharmaceuticals Ltd. completed a placement of AU$27.95 million (US$19.69 million) to advance its synthetic anti-infective pipeline to address antibiotic-resistant superbugs and emerging viral pathogens.
DUBLIN – Finch Therapeutics Inc. closed a $90 million series D round to take its oral microbiome therapy, CP-101, into late-stage clinical development and registration in chronic Clostridioides difficile infection and to move two additional programs, for chronic hepatitis B virus infection and autistic spectrum disorder, into the clinic.
DUBLIN – Adrenomed AG reported its anti-adrenomedullin antibody, adrecizumab, attained an absolute reduction of 9% in mortality as compared with placebo at both 14 and 28 days (D28) after treatment in a phase II trial in a large subgroup of patients with septic shock.
RSS
